354 related articles for article (PubMed ID: 20008302)
1. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Zonder JA; Crowley J; Hussein MA; Bolejack V; Moore DF; Whittenberger BF; Abidi MH; Durie BG; Barlogie B
Blood; 2010 Dec; 116(26):5838-41. PubMed ID: 20876454
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
Mitani Y; Usami E; Kimura M; Nakao T; Okada K; Matsuoka T; Kokuryou T; Yoshimura T; Yamakawa M
Pharmazie; 2016 Jun; 71(6):349-51. PubMed ID: 27455556
[TBL] [Abstract][Full Text] [Related]
9. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Khan ML; Reeder CB; Kumar SK; Lacy MQ; Reece DE; Dispenzieri A; Gertz MA; Greipp P; Hayman S; Zeldenhurst S; Dingli D; Lust J; Russell S; Laumann KM; Mikhael JR; Leif Bergsagel P; Fonseca R; Vincent Rajkumar S; Keith Stewart A
Br J Haematol; 2012 Feb; 156(3):326-33. PubMed ID: 22107129
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Hjorth M; Hjertner Ø; Knudsen LM; Gulbrandsen N; Holmberg E; Pedersen PT; Andersen NF; Andréasson B; Billström R; Carlson K; Carlsson MS; Flogegård M; Forsberg K; Gimsing P; Karlsson T; Linder O; Nahi H; Othzén A; Swedin A;
Eur J Haematol; 2012 Jun; 88(6):485-96. PubMed ID: 22404182
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Rajkumar SV; Rosiñol L; Hussein M; Catalano J; Jedrzejczak W; Lucy L; Olesnyckyj M; Yu Z; Knight R; Zeldis JB; Bladé J
J Clin Oncol; 2008 May; 26(13):2171-7. PubMed ID: 18362366
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
14. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Gay F; Rajkumar SV; Coleman M; Kumar S; Mark T; Dispenzieri A; Pearse R; Gertz MA; Leonard J; Lacy MQ; Chen-Kiang S; Roy V; Jayabalan DS; Lust JA; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Niesvizky R
Am J Hematol; 2010 Sep; 85(9):664-9. PubMed ID: 20645430
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS; Anderson T; Mietzel MA; Harvey CK; Wear SM; Barrickman JC; Tendler CL; Esseltine DL; Kelley SL; Kaminski MS; Anderson KC; Richardson PG
Blood; 2011 Jul; 118(3):535-43. PubMed ID: 21596852
[TBL] [Abstract][Full Text] [Related]
17. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
Cavo M; Zamagni E; Tosi P; Tacchetti P; Cellini C; Cangini D; de Vivo A; Testoni N; Nicci C; Terragna C; Grafone T; Perrone G; Ceccolini M; Tura S; Baccarani M;
Blood; 2005 Jul; 106(1):35-9. PubMed ID: 15761019
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Kumar SK; Lacy MQ; Hayman SR; Stewart K; Buadi FK; Allred J; Laumann K; Greipp PR; Lust JA; Gertz MA; Zeldenrust SR; Bergsagel PL; Reeder CB; Witzig TE; Fonseca R; Russell SJ; Mikhael JR; Dingli D; Rajkumar SV; Dispenzieri A
Am J Hematol; 2011 Aug; 86(8):640-5. PubMed ID: 21630308
[TBL] [Abstract][Full Text] [Related]
19. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Onishi Y; Yokoyama H; Katsuoka Y; Ito T; Kimura T; Yamamoto J; Nakajima S; Sasaki O; Ara T; Minauchi K; Fukuhara O; Kobayashi N; Noji H; Ota S; Harigae H
Ann Hematol; 2020 Oct; 99(10):2351-2356. PubMed ID: 32865607
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]